[go: up one dir, main page]

WO2004058807A3 - Mhc class i restricted t-cell stimulating peptides from hepatitis b virus - Google Patents

Mhc class i restricted t-cell stimulating peptides from hepatitis b virus Download PDF

Info

Publication number
WO2004058807A3
WO2004058807A3 PCT/EP2003/013948 EP0313948W WO2004058807A3 WO 2004058807 A3 WO2004058807 A3 WO 2004058807A3 EP 0313948 W EP0313948 W EP 0313948W WO 2004058807 A3 WO2004058807 A3 WO 2004058807A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
virus
restricted
mhc class
cell stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/013948
Other languages
French (fr)
Other versions
WO2004058807A2 (en
Inventor
Ignace Lasters
Johan Desmet
Toon Stegmann
Bernard Castelein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Algonomics NV
Original Assignee
Algonomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algonomics NV filed Critical Algonomics NV
Priority to AU2003293807A priority Critical patent/AU2003293807A1/en
Publication of WO2004058807A2 publication Critical patent/WO2004058807A2/en
Publication of WO2004058807A3 publication Critical patent/WO2004058807A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention related to peptides which are suitable for inducing an immune response to HBV and to the use of said peptides for the preparations of vaccines, compositions and in methods of diagnosis. Said sequences of said peptides are predicted using a method of the invention.
PCT/EP2003/013948 2002-12-24 2003-12-09 Mhc class i restricted t-cell stimulating peptides from hepatitis b virus Ceased WO2004058807A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003293807A AU2003293807A1 (en) 2002-12-24 2003-12-09 Mhc class i restricted t-cell stimulating peptides from hepatitis b virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02447276.3 2002-12-24
EP02447276 2002-12-24

Publications (2)

Publication Number Publication Date
WO2004058807A2 WO2004058807A2 (en) 2004-07-15
WO2004058807A3 true WO2004058807A3 (en) 2004-09-30

Family

ID=32668936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013948 Ceased WO2004058807A2 (en) 2002-12-24 2003-12-09 Mhc class i restricted t-cell stimulating peptides from hepatitis b virus

Country Status (2)

Country Link
AU (1) AU2003293807A1 (en)
WO (1) WO2004058807A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102796172B (en) * 2011-05-23 2015-03-25 中国科学院微生物研究所 Hepatitis B virus (HBV) specific human leukocyte antigen-A33 (HLA-A33) restrictive epitope peptides and application thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133241B2 (en) 2013-10-11 2015-09-15 Tarix Pharmaceuticals Ltd. Peptide compositions
BR112016007816A2 (en) * 2013-10-11 2017-12-05 Tarix Pharmaceuticals Ltd innovative peptide compositions
WO2015130488A2 (en) * 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
EP3181146A1 (en) * 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
KR102234027B1 (en) * 2018-05-09 2021-03-31 서울대학교산학협력단 Hepatitis b virus-derived polypeptide and use thereof
KR102711471B1 (en) * 2020-08-14 2024-09-30 서울대학교산학협력단 A pharmaceutical composition for preventing or treating cancer comprising hepatitis b virus-derived polypeptide
CN114591404B (en) * 2022-03-23 2024-12-10 成都朗谷生物科技股份有限公司 Hepatitis B virus antigen peptide suitable for individuals with leukocyte antigen haplotype HLA-A2 and its application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
US5932224A (en) * 1991-08-26 1999-08-03 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US6117653A (en) * 1987-06-22 2000-09-12 Medeva Holdings B.V. Hepatitis B surface antigen vaccine
WO2002019986A1 (en) * 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117653A (en) * 1987-06-22 2000-09-12 Medeva Holdings B.V. Hepatitis B surface antigen vaccine
US5932224A (en) * 1991-08-26 1999-08-03 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO2002019986A1 (en) * 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LOGEAN A ET AL: "RECOVERY OF KNOW T-CELL EPITOPES BY COMPUTATIONAL SCANNING OF A VIRAL GENOME", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, ESCOM SCIENCE PUBLISHERS BV, XX, vol. 16, no. 4, April 2002 (2002-04-01), pages 229 - 243, XP009008301, ISSN: 0920-654X *
NAYERSINA R ET AL: "HLA A2 RESTRICTED CYTOTOXIC T LYMPHOCYTE RESPONSES TO MULTIPLE HEPATITIS B SURFACE ANTIGEN EPITOPES DURING HEPATITIS B VIRUS INFECTION", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 150, no. 10, 15 May 1993 (1993-05-15), pages 4659 - 4671, XP000609159, ISSN: 0022-1767 *
TAN WEN SIANG: "Inhibition of hepatitis B virus assembly with synthetic peptides derived from the viral surface and core antigens", JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 48, no. 2, April 2002 (2002-04-01), pages 103 - 107, XP009031079, ISSN: 0022-1260 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102796172B (en) * 2011-05-23 2015-03-25 中国科学院微生物研究所 Hepatitis B virus (HBV) specific human leukocyte antigen-A33 (HLA-A33) restrictive epitope peptides and application thereof

Also Published As

Publication number Publication date
WO2004058807A2 (en) 2004-07-15
AU2003293807A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2004112831A3 (en) High titer recombinant influenza viruses for vaccines and gene therapy
EP1200109A4 (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
IL174983A0 (en) Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
FR2827605B1 (en) NOVEL PEPTIDES DERIVED FROM RSV PROTEIN G AND THEIR USE IN A VACCINE
WO2001037869A9 (en) Vaccine compositions
WO2006086188A3 (en) Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
IS7830A (en) Hepatitis C virus (HCV) vaccine
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
WO2005058349A3 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
WO2005027844A3 (en) Dna vaccine compositions and methods of use
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
WO2007121491A8 (en) Hcv vaccinations
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
WO2004041842A3 (en) Epitopes of hepatitis c virus
WO2006024240A3 (en) Vaccine composition against hepatitis c virus
IL149415A0 (en) Adjuvanted genetic vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP